GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Return-on-Tangible-Asset

BOLD (Boundless Bio) Return-on-Tangible-Asset : -31.70% (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Boundless Bio's annualized Net Income for the quarter that ended in Mar. 2025 was $-63.03 Mil. Boundless Bio's average total tangible assets for the quarter that ended in Mar. 2025 was $198.83 Mil. Therefore, Boundless Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -31.70%.

The historical rank and industry rank for Boundless Bio's Return-on-Tangible-Asset or its related term are showing as below:

BOLD' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -48.18   Med: -43.35   Max: -22.17
Current: -37.41

During the past 4 years, Boundless Bio's highest Return-on-Tangible-Asset was -22.17%. The lowest was -48.18%. And the median was -43.35%.

BOLD's Return-on-Tangible-Asset is ranked worse than
50.87% of 1498 companies
in the Biotechnology industry
Industry Median: -36.17 vs BOLD: -37.41

Boundless Bio Return-on-Tangible-Asset Historical Data

The historical data trend for Boundless Bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Return-on-Tangible-Asset Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
-22.17 -48.18 -47.83 -38.87

Boundless Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.98 -44.49 -36.35 -34.49 -31.70

Competitive Comparison of Boundless Bio's Return-on-Tangible-Asset

For the Biotechnology subindustry, Boundless Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boundless Bio's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Return-on-Tangible-Asset falls into.


;
;

Boundless Bio Return-on-Tangible-Asset Calculation

Boundless Bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-65.363/( (129.894+206.409)/ 2 )
=-65.363/168.1515
=-38.87 %

Boundless Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-63.032/( (206.409+191.242)/ 2 )
=-63.032/198.8255
=-31.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Boundless Bio  (NAS:BOLD) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Boundless Bio Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Traded in Other Exchanges
N/A
Address
10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.